PURPLE BIOTECH LTD. annual report, Q4 FY2019

Business context and reporting period

This is Kitov Pharma Ltd.’s audited annual report on Form 20-F for the fiscal year ended December 31, 2019, not a standalone fourth-quarter filing. The supplied filing identifies the issuer as Kitov Pharma Ltd.; it does not identify the company as Purple Biotech.

Kitov reported two business segments: Pain and Hypertension, centered on FDA-approved Consensi, and Oncology, focused in 2019 on preclinical candidate NT219. The FameWave acquisition, which brought clinical-stage candidate CM-24, closed on January 7, 2020. Financial statements are prepared under IFRS as issued by the IASB. The auditor gave an unqualified opinion on the financial statements.

Financial results and liquidity

Amounts are U.S. dollars in millions unless stated otherwise.

Management reported adjusted operating loss, a non-IFRS measure, of $5.883 million for 2019 versus $7.053 million for 2018, excluding non-cash share-based compensation. The measure is not a substitute for IFRS results.

Material changes and developments

• Revenue remained $1.0 million, but its source shifted: 2019 revenue was a Consensi commercialization milestone from Coeptis; 2018 revenue came from Consensi agreements in China. The filing reports no royalties from product sales in either year.
• Lower R&D spending helped reduce operating loss, while reported net loss rose slightly as financing income was lower and tax expense arose. The 2019 financing result depended substantially on warrant fair-value accounting.
• Operating cash use improved, but cash and cash equivalents declined by $0.778 million during the year. Financing activities provided $5.233 million; investing activities used $0.449 million.
• The company issued ADSs and warrants in January 2019, and ordinary shares outstanding rose to 19.564 million at year-end from 16.009 million at the end of 2018. A 1-for-20 reverse share split took effect January 4, 2019.

Outlook, risks, contingencies, and unusual items

• Commercial outlook: Consensi’s U.S. launch was planned for 2020. Under the amended Coeptis agreement, Kitov described 20% royalties on net sales, minimum royalties of $4.5 million over three years, and up to $99.5 million in milestones and reimbursement payments. The filing expected aggregate milestone and royalty revenue of $28–$36 million from 2020 through 2022; these are expectations, not guaranteed revenue or formal earnings guidance.
• Pipeline plans: Kitov expected to submit an IND for NT219 in the first half of 2020 and planned a Phase 1/2 study. A CM-24 Phase 1/2 combination study with Bristol Myers Squibb’s nivolumab was planned for the second half of 2020. Both plans were subject to regulatory, clinical, manufacturing, funding, and collaboration risks.
• Funding: Management said existing working capital was expected to meet requirements for at least 12 months, but also stated that development plans and future financing needs were uncertain and additional capital might be required. After year-end, the company raised $3.5 million in connection with the FameWave transaction and approximately $5.2 million net in a March 2020 public offering. Those proceeds are subsequent events, not 2019 operating cash flow.
• Acquisition and commitments: FameWave closed in January 2020; Kitov had advanced a $2.0 million loan, reported as a financial asset at year-end. The filing also describes a $6.4 million CM-24 manufacturing agreement with Rentschler over two years, entered into in 2020, and notes that FameWave manufacturing obligations were not included in the year-end contractual-obligations table.
• Legal matters: The 2019 ISA enforcement arrangement included a company fine of NIS 1.5 million (about $0.43 million), payable over 24 months. U.S. securities class actions settled for $2.0 million, funded by insurance. Israeli class-action matters remained pending; management could not reliably assess the probability or potential exposure for some claims. The company reported $2.086 million in legal expenses through year-end related to the investigation and class actions, with $1.403 million reimbursed by insurers to date.
• Listing and dilution: Nasdaq had granted an additional compliance period through July 6, 2020 to remedy the ADS bid-price deficiency; a reverse split was among the options considered. The March 2020 financing added substantial ADSs, pre-funded warrants, and warrants, creating potential dilution.
• Other risks and accounting: The filing flagged COVID-19 uncertainty, including possible disruption to trials, supply chains, and regulatory inspections; foreign-exchange exposure; IIA grant-related royalty and technology-transfer restrictions; and possible PFIC status for U.S. investors. IFRS 16 adoption in 2019 brought lease assets and liabilities onto the balance sheet. Management reported effective disclosure controls and internal control over financial reporting; no auditor attestation on internal controls was included under the emerging-growth-company exemption.

Important facts an investor should verify

• Confirm the issuer identity and reporting period: the supplied filing is Kitov Pharma Ltd.’s FY 2019 Form 20-F, not a quarterly report and not identified in the text as Purple Biotech.
• Check subsequent filings for actual Consensi launch, U.S. sales, royalties, milestone receipts, and whether the stated $28–$36 million revenue expectation was achieved.
• Verify post-year-end cash, operating runway, financing terms, fully diluted share count, and warrant exercises against later filings.
• Track IND clearance and clinical progress for NT219 and CM-24, including the status and terms of the BMS collaboration and the Rentschler manufacturing commitment.
• Review the status and potential cost of the remaining Israeli litigation, insurance coverage, and payment of the ISA fine.
• Confirm whether Kitov cured the Nasdaq bid-price deficiency by the deadline and whether any reverse split or other listing action followed.